Skip to content

10 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

Simplified BMI-stratified diagnostic NT-proBNP thresholds in patients with HFpEF

Obesity is associated with lower natriuretic peptide concentrations, potentially reducing the diagnostic accuracy of N-terminal pro–B-type natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF). Several body mass index (BMI)–adjusted NT-proBNP thresholds have been proposed, but...

R. Ono, R. Campbell, A. Henderson et al. · 0 citations
Open access Oct 2026

NT-proBNP and Clinical Outcomes in Patients With HFrEF According to Atrial Fibrillation: Insights From QUEST.

BACKGROUND The Chinese traditional medicine qiliqiangxin (QLQX) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) when added to guideline-directed medical therapy. OBJECTIVES This post hoc analysis of the QUEST (Qiliqiangxin in Heart Failure: Assessment of Reduction in Mortality)...

L. Shen, Jun-Ru Li, I. Cheang et al. · 0 citations
Open access Oct 2026

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces left ventricular (LV) volumes in heart failure with reduced ejection fraction (HFrEF). Whether this effect is additive to optimal background guideline-recommended therapy is unknown. To evaluate the effects of empagliflozin according to key...

M. Lee, C. Berry, R. Campbell et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations
Oct 2026

Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement.

Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently...

R. Inciardi, A. Abdin, M. Abdelhamid et al. · 0 citations
Open access Sep 2026

Artificial intelligence detection of heart failure on coronary computed tomography angiography: external validation in patients with non-ST-segment elevation acute coronary syndrome

Artificial intelligence-based CCTA analysis identified a large low-risk subgroup and a smaller subgroup at increased HF risk, supporting further evaluation of opportunistic HF assessment from CCTA.

A. O. Olesen, K. Miger, S. Ørting et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.